Search
Microcrystalline cellulose
go.drugbank.com/drugs/DB14158ApprovedInvestigationalIt is the chief constituent of plant fibers, cotton being the purest natural form of the substance.
Oxyphenonium
go.drugbank.com/drugs/DB00219ApprovedThe drug has also been used in the form of eye drops for mydriatic effect. [PubChem]
Nilutamide
go.drugbank.com/drugs/DB00665ApprovedInvestigationalNilutamide is a pure, nonsteroidal anti-androgen with affinity for androgen receptors (but not for progestogen, estrogen, or glucocorticoid receptors).
Aprocitentan
go.drugbank.com/drugs/DB15059ApprovedInvestigational[A263386,L50261] Aprocitentan was approved by the FDA in March 2024 for the treatment of hypertension in patients inadequately controlled with standard therapy.
Acadesine
go.drugbank.com/drugs/DB04944InvestigationalIt is being developed jointly by PeriCor and Schering-Plough. Acadesine has been granted Orphan Drug Designation for B-CLL in the EU.
Barnidipine
go.drugbank.com/drugs/DB09227InvestigationalIn two European multicentre randomized, double-blind trials, barnidipine was shown to possess equivalent antihypertensive efficacy to amlodipine and nitrendipine, but produced fewer class-specific side-effects … According to a dose-ranging, multicentre, placebo-controlled, double-blind study in patients with mild to moderate hypertension, the antihypertensive response from barnidipine treatment was maintained
Stem-cell derived exosome vesicle products
go.drugbank.com/drugs/DB15743ExperimentalOnce secreted into extracellular fluid, exosomes are taken up by their target cells or carried to distant target sites. … These products originate from multiple cellular types, including immunocytes, tumor cells, and mesenchymal stem cells (MSCs) originating from various tissues.
TTP889
go.drugbank.com/drugs/DB05131InvestigationalTTP889, an orally bioavailable selective inhibitor of the intrinsic coagulation pathway, is being developed as an anticoagulant for the treatment of thromboembolic disorders. TTP889 is the only known selective small molecule inhibitor of...
Cimicoxib
go.drugbank.com/drugs/DB05095InvestigationalIf approved, Cimicoxib would be the first drug in decades to treat depression by a new mechanism of action. … Cimicoxib is a selective COX-2 inhibitor being developed by Affectis as a treatment for depression and schizophrenia.
Cocamidopropyl betaine
go.drugbank.com/drugs/DB11350ApprovedCocamidopropyl betaine is a mixture of closely related organic compounds derived from coconut oil and dimethylaminopropylamine that typically acts as an amphoteric surfactant in cosmetics and personal